{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001281895","name":"ROCKET PHARMACEUTICALS, INC.","summary":"Rocket Pharmaceuticals, Inc. is a clinical-stage gene therapy company developing treatments for rare, devastating diseases. Its pipeline includes lentiviral vector (LV) and adeno-associated virus (AAV) based therapies targeting conditions such as Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD), Danon Disease (DD), PKP2-Arrhythmogenic Cardiomyopathy (PKP2-ACM), BAG3-Dilated Cardiomyopathy (BAG3-DCM), and other rare genetic and cardiac disorders.","people":[],"products":[{"name":"FA Gene Therapy","type":"platform","description":"Lentiviral vector-based gene therapy for Fanconi Anemia, a rare inherited bone marrow failure disorder."},{"name":"LAD-I Gene Therapy","type":"platform","description":"Lentiviral vector-based gene therapy for Leukocyte Adhesion Deficiency-I, a rare primary immunodeficiency."},{"name":"PKD Gene Therapy","type":"platform","description":"Lentiviral vector-based gene therapy for Pyruvate Kinase Deficiency, a rare red blood cell disorder."},{"name":"Danon Disease Gene Therapy","type":"platform","description":"AAV-based gene therapy targeting LAMP2 mutations causing Danon Disease, a rare lysosomal storage disorder."},{"name":"PKP2-ACM Gene Therapy","type":"platform","description":"AAV-based gene therapy for Plakophilin-2 Arrhythmogenic Cardiomyopathy, a rare inherited heart disease."},{"name":"BAG3-DCM Gene Therapy","type":"platform","description":"AAV-based gene therapy for BCL2-associated athanogene 3 mutations associated with dilated cardiomyopathy."}],"partnerships":[{"partner_name":"CIEMAT","partnership_type":"development","description":"Part of CIEMAT Group collaborating on gene therapy research and development.","start_date":null},{"partner_name":"CIBER","partnership_type":"development","description":"Part of CIEMAT Group collaborating on gene therapy research.","start_date":null},{"partner_name":"FIISFJD","partnership_type":"development","description":"Part of CIEMAT Group (Fundacion Instituto de Investigación Sanitaria Fundacion Jiménez Díaz) collaborating on gene therapy.","start_date":null},{"partner_name":"Stanford Center for Definitive and Curative Medicine","partnership_type":"development","description":"Collaboration with Stanford University School of Medicine on gene therapy programs.","start_date":null},{"partner_name":"UCLA","partnership_type":"development","description":"University of California, Los Angeles listed as a partner/collaborator.","start_date":null},{"partner_name":"UCSD","partnership_type":"development","description":"The Regents of the University of California, San Diego listed as a partner/collaborator.","start_date":null},{"partner_name":"NIH","partnership_type":"development","description":"National Institutes of Health listed as a collaborating institution.","start_date":null},{"partner_name":"CIRM","partnership_type":"development","description":"California Institute for Regenerative Medicine listed as a funding/collaborating partner.","start_date":null},{"partner_name":"Lexeo Therapeutics, Inc.","partnership_type":"strategic","description":"Lexeo Therapeutics listed as a related entity in the filing.","start_date":null},{"partner_name":"RTW Investments, L.P.","partnership_type":"strategic","description":"RTW Investments listed as a notable investor/partner.","start_date":null},{"partner_name":"Hospital Infantil de Niño Jesús (HNJ)","partnership_type":"development","description":"Spanish pediatric hospital listed as a clinical collaborator.","start_date":null},{"partner_name":"UCL Business PLC","partnership_type":"licensing","description":"UCLB listed as a licensing/collaboration partner for gene therapy technology.","start_date":null}],"affiliations":[],"origin":{"leaf":"3cfdbaed0c21082be9016c147be928ff768932ac647247f15b2ca6f2c2d08866","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"c8034be83a4a2d5175c0506f1710c0474f32d313608f32301029b20c8f7126bc","parent":"440b244e97b158423667ecf42120bcce673288862dd1b31e2a8a417007468e04","source":"0001193125-26-076551","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":119,"hourly_limit":500,"remaining":381,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}